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Abstract
The extrahepatic manifestations of hepatitis B virus (HBV) infection include reactive arthritis, vasculitis (panarteritisnodosa), and primary glomer-
ulonephritis (membranous nephropathy, membranoproliferative glomerulonephritis, and, less frequently, IgA nephropathy, focal and segmental 
glomerulosclerosis, and minimal change disease). No specific histomorphological patterns have been reported in association with HBV infection. 
The treatment of HBV-related glomerulopathies is essentially antiviral. Peginterferon and nucleos(t)ide drugs are the treatment of choice. Cortico-
steroids have been proved to be ineffective (except in panarteritisnodosa), while immunosuppressants can lead to exacerbation of HBV infection.
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Introduction
Hepatitis B virus (HBV) is probably the most common virus 
found globally, affecting approximately 400 million subjects 
worldwide, although its incidence is decreasing due to the vac-
cination. The most severe complication is the hepatocellular 
carcinoma (HCC) that represents the ninth cause of death (1). 
In addition to the hepatic disease, the HBV is a frequent cause 
of extra hepatic disorders, among which the most common 
are glomerulonephritis (GN), vasculitis, and arthritis.
Genetic and Structure of HBV
HBV may be distinguished in 10 different genotypes; each 
of  them is further divided in several subtypes. Genotypes 
are distinguished according to alphabetical letters. Accord-
ing to the genotype and subtype, HBV has a different 
geographical localization and causes different aggressive 
diseases (2).
Initially, genotype A seemed to be the most frequent cause 
of glomerular disease (3), but, subsequently, a more accurate 
study (4) has not confirmed a significant association between 
HBV genotype and renal disease.
HBV is a member of Hepadnaviridae. HBV genome is rep-
resented by a round DNA. There are four genes encoded by 
the genome: C, X, P, and S. The core protein is encoded by 
the C gene (HBcAg). The early antigen (HBeAg) is derived 
from a proteolytic action of gene P. Gene S encodes the 
surface antigen (HBsAg) (5, 6). The structure of HBV is 
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membranous nephropathy is further documented by the fact 
that circulating HBeAg containing immune complexes cor-
relate with the severity of the disease (13, 14).
After glomerular deposition or formation of immune com-
plexes, the complement activation could justify glomerular 
damage (15, 16). Figure 1 explains the relationship between 
the antigens and the type of glomerular disease.
Direct viral effect
The expression of HBV-DNA in the glomeruli in the absence 
of antibodies could justify the direct effect of HBV in glo-
merular damage (17).
Diao et al. (18), putting in culture together with mesangial 
cells and HBV, documented cell proliferation and formation 
of extracellular matrix proteins.
Host and viral genetic factors
HBV-associated glomerular disease may be linked to spe-
cific major histocompatibility complex class II alleles such as 
DQB1*0603 for membranous nephropathy and DRB1*1502 
for MPGN (19, 20).
We have mentioned the possible relationship between differ-
ent genotypes of HBV and associated nephropathy. Further 
studies have found that mutations in HBV genes (C1653T, 
A1726C, A1727T, C1730G, T1753C, A1762T, and G1764A) are 
present in 84% of patients with membranous nephropathy (21).
Clinical Aspects
Membranous nephropathy
The natural history of HBV-related membranous nephropa-
thy seems to differ in children and adults.
important to explain its effects and, in particular, different 
pathogenetic pathways of glomerular disease.
Extra Hepatic Manifestations of HBV Infection
The principal targets of HBV are hepatocytes. According 
the status of viral replication, different conditions have been 
described ranging from an immune-tolerant phase to an 
immune-reactive phase with occurrence of hepatic necrosis 
and fibrosis. As this phase prolongs or repeats, fibrogenesis 
develops with subsequent cirrhosis. HCC is a major complica-
tion that can occur in the presence or absence of cirrhosis (7).
Extra hepatic manifestations of HBV infection may include 
dermatological manifestations, such as keratolysis, urticaria, 
purpura, and lichen planus, systemic diseases, such as serum 
sickness syndrome, polyarthralgia, polyarthritis, and, most 
importantly, renal diseases (7, 8). The latter include membra-
nous nephropathy (MN), membranoproliferative glomerulo-
nephritis (MPGN), immunoglobulin A (IgA) nephropathy, 
and focal segmental glomerulosclerosis (FSGS) (9). Less 
frequently, minimal change disease (MCD) and amyloido-
sis have been described in association with HBV, although 
this association is debated. Additionally, polyarteritisnodosa 
(PAN) is strongly associated with HBV. The disease is char-
acterized by a necrotizing small and medium vessel vasculitis.
Pathogenesis
Three different factors may contribute to the development of 
HBV-associated renal diseases:
1. HBV antigens containing immune complexes
2. Direct viral effect
3. Host and viral genetic factors
Immune complexes
The role of immune complexes containing an HBV antigen 
is a certain factor, although it is still controversial whether 
the immune complexes are formed in situ or come from the 
blood and trapped into glomerular structures.
Several HBV antigens have been documented in the glom-
eruli, including the surface antigen (HBsAg), the early anti-
gen (HBeAg), and the core antigen (HBcAg) (10). HBsAg 
and HBcAg are large and cationic. Owing to the dimension 
and charged immune complexes, these antigens could favor 
the mesangial or subendothelial deposition and facilitate the 
development of MPGN or IgA nephropathy. Indeed, immune 
complexes containing HBsAg have been eluted from a patient 
affected by HBV-MPGN (11). The low molecular weight 
of HBcAg (300 kilodalton) and its cationic charge could 
favor transmembrane migration and their deposition in the 
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Figure 1: Glomerular syndromes associated with an HBV 
carrier state. MN: membranous nephropathy; MPGN: 
membrano proliferative glomerulonephritis; PAN: polyarte-
ritisnodosa; MC: mixed cryoglobulinemia; FSGS: focal seg-
mental glomerulonephritis.
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vessels due to deposition of HBsAg antibodies immune 
complexes (36).
With respect to idiopathic PAN, HBV patients have a 
more severe disease with frequent evolution to AKI due to 
renal ischemia and infarction. Arthralgia, fever, and cutane-
ous lesions are present. Additionally, elevated hypertension 
and renal infarctions of the cortex are also present. A case of 
HBV-positive patient with associated PAN and membranous 
nephropathy has been described by Mouthon et al. (37).
Other glomerulonephritis
The first description of mesangial proliferative glomerulo-
nephritis with mesangial deposition of IgA and HBsAg or 
HBcAg has been made by Nagy et al. (38). Lai et al. (39) 
described a larger series of patients with HBV-associated 
mesangial proliferative glomerulonephritis. Approximately 
20% of patients developed progressive renal failure within 
4 years of follow-up, but this finding was not confirmed by 
others (40).
Relationship between FSGS and HBV is debated. Two 
cases have been described by Khaira et al. (41). The find-
ing of HBsAg or HBcAg in the glomeruli in the absence of 
immunoglobulins suggests the role of a direct pathogenic 
effect of the virus.
MCD and diffused proliferative glomerulonephritis have 
been described in HBV-positive patients (42), but because of 
few cases reported, more confirmative studies are needed.
Diagnosis
The diagnosis of an HBV-related renal disease should be sus-
pected for any HBV-positive patient with an abnormal urine 
analysis or a reduced renal function.
Patients with proteinuria, higher than 1 g (24 h), and 
microematuria are suspected for glomerular lesions. In such 
cases, a renal biopsy is necessary to confirm the suspected 
diagnosis (Figure 2). The diagnosis of HBV-related glomer-
ular disease is confirmed by finding monoclonal antibod-
ies and one or more HBV antigens (HBsAg, HBcAg, or 
HBeAg), although in one study only 39% of biopsies were 
positive (43). In the case of HBV-related PAN, urine-analysis 
may be negative, and a definitive diagnosis should be made 
by angiography (44).
Treatment
The vast majority of our knowledge on the treatment of 
HBV-related GNs relies on studies on membranous nephrop-
athy, while data on MPGN or other glomerular diseases 
principally refer to case reports.
The main goal of the treatment is to reduce viral load. 
Antiviral treatment is effective in inducing HBV clearance 
Children often present with proteinuria in the nephrotic 
range with associated microematuria and hypertension. 
Kidney function as evaluated by estimated glomerular filtra-
tion rate (eGFR) is generally preserved. The natural history 
in children is often benign with a remission rate of 64% at 
4 years (22). The disease prevails in males as idiopathic MN 
(23). HBV-MN in adults has a worse evolution in compari-
son to children. A declining eGFR has been observed in 29% 
of patients and one-third patients develop end-stage renal 
disease (ESRD) (24).
The deposition of immune complexes is typically in the 
subepithelial space because of their small size. Segmental 
glomerular damage and mesangial cell proliferation are more 
frequent in the idiopathic form (25). Some studies have doc-
umented the simultaneous presence of subendothelial and 
mesangial deposits in HBV-MN (26, 27).
Immune complexes may also be formed by implant anti-
gens, and the presence of complement factors, platelet 
aggregation, and polymorphonuclear leukocytes may justify 
glomerular damage (28).
Finally, the direct effect of the virus has been suggested in 
HBV-MN also. Several studies have found HBV DNA in the 
nucleus and cytoplasm of epithelial and mesangial cells (29).
In the vast majority of patients, pathological basis is 
not possible to distinguish the HBV-related MN from the 
idiopathic MN. The only method available is based on 
the finding of circulating anti-phospholipase A2 receptor 
Ab (30, 31).
Membranoproliferative glomerulonephritis
MPGN is the second most common glomerulonephritis in 
HBV-positive patients. It is characterized by lobular aspects 
of the glomeruli because of mesangial proliferation. The 
splitting of glomerular basement membrane (GBM) is due 
to the infiltration of mesangial cells and their deposition in 
the subendothelial space of immune complexes containing 
HBsAg because of its size (32–34). Type 1 and type 3 MPGN 
have been observed in HBV-positive patients, while type 2 
has been never observed (35).
Presence of mixed cryoglobulinemia (polyclonal IgM and 
IgG) has been described in HBV-positive patients. As cryo-
globulinemia is mostly typical of HCV infection, a co-infec-
tion of HBV-HCV should be excluded.
HBV-positive patients with cryoglobulinemia have 
nephrotic syndrome, frequently with acute kidney injury 
(AKI) and vasculitis with low C3 and C5 levels in serum.
Polyarteritisnodosa
Although PAN is not strictly a renal disease, its evidence is 
high in HBV-positive patients with occurrence of a renal 
disease. PAN is a vasculitis with necrosis of medium size 
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and proteinuria remission (45, 46). In 2012, the Kidney 
 Disease: Improving Global Outcomes (KDIGO) guidelines 
on glomerulonephritis recommended interferon alpha 
(IFNα) with nucleos(t)ide analogs (NAs) as the treatment of 
choice for HBV-GN (47).
Initially, the antiviral treatment was based on IFNα and 
lamividine (LMV). Their use was effective in reducing pro-
teinuria, principally in children with membranous nephropa-
thy (48, 49). According these studies the renal prognosis was 
different in children and adults. Indeed, the occurrence of 
ESRD was 3% in children and 30% in adults.
Main drawback of LMV was the appearance of mutants 
resistant to therapy (50).
The peginterferon (PEG-IFN) alpha-2a is a more pow-
erful treatment because it has both immune regulatory and 
antiviral action (51).
IFNα could induce proliferation of T lymphocytes and 
helper T cells (52).
Patients affected with HBV-related MN have a reduced 
TCD28-related cytotoxic activity, and IFNα treatment has 
an effective activity in 30–40% of patients with clearance of 
HBeAg (53).
Other NAs, in addition to LMV, used to date are ente-
cavir (ETV), adefovir (ADV), telbivudine (TBV), and 
tenofovir (TAF), although LMV, ADV, and TBV are not rec-
ommended for treating chronic HBV infection (54).
ETV is effective with low resistance (55). Its dosage should be 
reduced according to renal function (56). ADV is effective for 
liver improvement, viral suppression, and biochemical improve-
ment in patients resistant to LMV (57, 58). A major drawback 
of ADV is dose-dependent nephrotoxicity that could be avoided 
by maintaining a dose of 10 mg/daily (59, 60).
Use of TBV is limited due to the emergence of drug resis-
tance that may reach 25.1% in 2 years of treatment (61, 62). 
Additionally, TBV may cause myopathy and peripheral neu-
ropathy (63).
TAF is a better-known NA and is used as two variants: 
tenofovirdisoproxil fumarate (TDF) and tenofoviralafenam-
ide (TAF).
TDF is effective on HBV, but is nephrotoxic because of 
tubular injury (63). Because of this fact, TDF should be 
avoided in the treatment of HBV-related GN. More prom-
ising is TAF, which seems to have a reduced nephrotoxicity 
with a similar antiviral action (64, 65). TAF seems to have 
a higher antiviral activity and reduced nephrotoxicity than 
TDF, though few studies have compared the two drugs.
The WHO (56) recommends the dose reduction of TAF 
and ETV according to renal function (creatinine clearance) 
as shown in Table 1.
Although the aim of this study was to review principal 
treatments for HBV-related GN, briefly we report the conclu-
sions of the Swedish guidelines (66) for the use of PEG-IFN 
and NAs.
PEG-IFN has a weak antiviral effect compared to NAs. 
A small number of HBeAg-positive and negative patients 
obtained HBsAg clearance. In addition, PEG-IFN is poorly 
tolerated and necessitates parenteral administration.
NAs have a major potency in elimination of virus. ETV, 
TDF, and TAF are recommended because these drugs have 
a higher barrier to drug resistance. On the contrary, LMV, 
ADV, and TBV with low barrier to drug resistance are not 
recommended.
ETV, whose dose should be reduced according eGFR, is 
the preferred treatment for naïve, non-cirrhotic HBeAg-pos-
itive patients. Attention should be paid to cross-resistance 
with LMV.
TDF is a highly effect treatment and has been approved as 
a monotherapy for the treatment of HBV. Risks of renal side 
effects do exist; hence, renal function should be monitored 
frequently.
TAF has the same mode of action as that of TDF, with 
fewer side effects on the kidney, and does not need to be 
Signs and symptoms suggestive of renal involvement in HBV infection
Urinalysis (24 hour urine protein >1 g/day, RBC casts
Renal biopsy
Pattern consistent with HBV-related glomerulonephritis: 
Membranous, Membrano-proliferative, IgA nephropathy 
Figure 2: Diagnostic steps for diagnosing HBV-related glomerulonephritis.
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Table 1: Recommended dose reduction or dosing interval for tenofovir and entecavir.
CrCl (mL/min)
50 30–49 10–29 Hemodialysis
Tenofovir (TAF) 300 mg every 24 h 300 mg every 48 h 300 mg every 72 h Every 7 days
Entecavir (ETV) 1 mg once daily 0.5 mg once daily 0.3 mg once daily 0.1 mg once daily
CrCl: creatinine clearance.
Table 2: Outcomes from treatment of HBeAg-positive and negative patients, 6-month and after 1-year treatment with PEG-
IFN, and after 1-year treatment with nucleos(t)ide analogs (NAs).
PEG-IFN alpha 2a LMV TBV ETV ADV TDF TAF
Dose 180 μg 100 mg 600 mg 0.5 mg 10 mg 245 mg 25 mg
HBeAg-positive
Anti-HBe seroconversion 32% 16–18% 22% 21% 12–18% 21% 10%
HBV DNA < 60–80 IU/mL 14% 36–44% 60% 67% 13–21% 76% 64%
ALT > ULN 41% 41–72% 77% 68% 48–54% 68% 72%
Loss of HBsAg 3% 0–1% 0.5% 2% 0% 3% 1%
HBeAg-negative
HBV DNA < 60–80 IU/mL 19% 72–73% 88% 90% 51–63% 93% 94%
ALT < normal upper limit 59% 71–79% 74% 78% 72–77% 76% 83%
Loss of HBsAg 4% 0% 0% 0% 0% 0% 0%
PEG-IFN: peginterferon; LMV: lamividine; TBV: telbivudine; ETV: entecavir; ADV: adefovir; TDF: tenofovirdisoproxil 
fumarate; TAF: tenofovir.
LAM, TBV, and ETV are nucleoside analogues; and ADV, TDF, and TAF are nucleotide analogues.
monitored, although not recommended for patients with a 
very low eGFR.
The Swedish guidelines (66) report the outcomes of different 
NAs in HBeAg-positive and HBeAg-negative patients (Table 2).
Summarizing, the wider experience of the effects of antivi-
ral treatments in HBV-GN is based on the studies conducted 
with LMV and IFNα therapy. Studies comparing the efficacy 
of new NAs and IFNα are still lacking. Anyway, HBV-GN 
goes into remission with the elimination of viral antigen 
(67–69). This fact favors the use of NAs with high potency. 
However, more studies are needed to confirm this point.
Immunosuppressants are also used frequently in the treat-
ment of HBV-GN.
The usefulness of steroids is debated because the inhibition 
of the immune system may favor HBV replication (70). In a 
meta-analysis study, the steroid efficacy is not proved (45). In 
this study, both proteinuria remission and HBeAg clearance 
were obtained with the use of antiviral agents.
Administration of steroids is not recommended princi-
pally in patients with high viral load.
Similarly, the use of rituximab and cytotoxic agents may 
cause fatal complications (71, 72).
Only in the treatment of HBV-PAN, the association of ste-
roids and plasmapheresis has been used successfully (73).
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